Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Streptozotocin · 1 trial · 1 indication
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression. Median PFS was estimated using the Kaplan-Meier method.
PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| bevacizumab [Avastin] | DRUG | 7.5mg/kg iv on day 1 every 3 weeks |
| 5 FU | DRUG | 400mg/m2/day iv on days 1-5 every 6 weeks |
| Streptozotocin | DRUG | 500mg/m2/day iv on days 1-5 every 6 weeks |
| Xeloda | DRUG | 1000mg/m2 po bid on days 1-14 every 3 weeks |
Inclusion Criteria: * adult patients, \>=18 years of age; * well-differentiated gastrointestinal tract endocrine tumors, or duodeno-pancreatic endocrine tumors; * no previous anti-cancer therapy, other than surgery; * progressive metastatic disease; * \>=1 measurable lesion. Exclusion Criteria: *...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Streptozotocin is used for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being studied in the context of oncology, specifically for endocrine tumors of the gastrointestinal tract, as part of a combination chemotherapy regimen.
Streptozotocin is a small molecule that works by targeting and destroying insulin-producing beta cells in the pancreas. This mechanism makes it useful in treating certain types of pancreatic tumors, particularly those that arise from these cells, such as insulinomas.
Streptozotocin is being developed by Roche Holding AG, a multinational healthcare company. The company's stock is traded under the ticker symbol RHHBY on the OTC market.
Streptozotocin is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
Streptozotocin was studied in a completed Phase 2 clinical trial with the identifier NCT00448136. This trial, titled 'A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract,' enrolled 83 participants in France.
Streptozotocin is a distinct chemical compound and is not known to be the same as other drugs. It is a small molecule with a unique structure that specifically targets pancreatic beta cells, making it different from other chemotherapy agents.